RMC-6236

Phase 3Small molecule

Revolution Medicines

RMC-6236 is one of 270 small molecule programs targeting Pancreatic Ductal Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

269

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic Ductal AdenocarcinomaActive, not recruiting

Colorectal CancerRecruiting

Pancreatic CancerRecruiting

Non-Small Cell Lung Cancer (NSCLC)Recruiting

EfficacyRecruiting

Solid TumorsRecruiting

Patients With Advanced Solid TumorsRecruiting

Pancreatic Ductal AdenocarcinomaPhase 3

Active, not recruiting

Colorectal CancerPreclinical

Recruiting

Pancreatic CancerPhase 1

Recruiting

Non-Small Cell Lung Cancer (NSCLC)Preclinical

Recruiting

EfficacyPreclinical

Recruiting

Solid TumorsPhase 1

Recruiting

Patients With Advanced Solid TumorsPhase 2

Recruiting

Competition

Competitive Landscape

307 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

RMC-6236

Revolution Medicines

Phase 3

1 2

Byetta

AstraZeneca

Preclinical

1 3

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 5

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 6

Active Comparator

Moderna

Preclinical

1 7

Secretin-Ferring

Ferring

Preclinical

1 8

Sulfonylureas

Eli Lilly

Preclinical

1 9

Hyperpolarized 13c Pyruvate

UUniversity of Maryland, Baltimore

Preclinical

1 10

Cyclophosphamid

EEssen Biotech

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Solid Tumors

NCT06040541

Q3 2027

Phase 1/2Recruiting

Patients With Advanced Solid Tumors

NCT05379985

Q4 2027

Phase 3Active, not recruiting

Pancreatic Ductal Adenocarcinoma

NCT06625320

PreclinicalRecruiting

PDAC

NCT06922591

Q4 2028

PreclinicalRecruiting

Non-Small Cell Lung Cancer (NSCLC)

NCT06162221

Clinical

Trials by Indication[1]

Solid Tumors1 trial

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Recruiting· Revolution Medicines logo

Revolution Medicines·Phase 1·NCT06040541·604 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Active, not recruiting· Revolution Medicines logo

Revolution Medicines·Phase 3·NCT06625320·501 enrolled

Patients With Advanced Solid Tumors1 trial

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Recruiting· Revolution Medicines logo

Revolution Medicines·Phase 1/2·NCT05379985·754 enrolled

Pancreatic Cancer1 trial

A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

Recruiting· Amgen logo

Amgen·Phase 1·NCT06360354·350 enrolled

PDAC1 trial

A Phase 1/2, Multicenter, Open-Label Study to Evaluate Safety, Tolerability & Antitumor Activity of TNG462 in Combination With Other Agents in Patients With Pancreatic Cancer With MTAP Loss and Pancreatic or Non-Small Cell Lung Cancer With MTAP Loss & RAS Mutation

Recruiting·TTango Therapeutics, Inc.·Preclinical·NCT06922591·183 enrolled

2 more indications

Non-small Cell Lung Cancer (NSCLC)1 trial

A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)

Recruiting· Revolution Medicines logo

Revolution Medicines·Preclinical·NCT06162221·616 enrolled

Colorectal Cancer1 trial

A Platform Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Recruiting· Revolution Medicines logo

Revolution Medicines·Preclinical·NCT06445062·1,130 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for RMC-6236. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RMC-6236 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RMC-6236. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Revolution Medicines company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Revolution Medicines

RMC-6236

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Q4 2027

Q4 2028

Trials by Indication[1]

Solid Tumors1 trial

Pancreatic Ductal Adenocarcinoma1 trial

Patients With Advanced Solid Tumors1 trial

Pancreatic Cancer1 trial

PDAC1 trial

Non-small Cell Lung Cancer (NSCLC)1 trial

Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News